MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202617065022 A) filed by Capstan Therapeutics, Inc. on May 22, 2026, for Rna For In Vivo Transfection With Increased Expression.
Inventors include Matsuda, Daiki; Khoshnejad, Makan; Zhang, Yan; Nguyen, Duy; Yong, Qian-Chen; Aghajanian, Haig; Bot, Adrian, Ion; Karmali, Priya, Prakash; and Sievers, Stuart, Aaron.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5' untranslated region (UTR) and 3' UTR, particular 3' UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.
Disclaimer: Curated by HT Syndication.
